# A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

> **NCT04762498** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 50 (actual)

## Conditions studied

- Uncontrolled Gout
- Chronic Gout

## Interventions

- **BIOLOGICAL:** Pegloticase
- **DRUG:** Methotrexate (MTX)

## Key facts

- **NCT ID:** NCT04762498
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-26
- **Primary completion:** 2023-05-18
- **Final completion:** 2023-12-20
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04762498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04762498, "A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT04762498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*